| Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemia DA Pollyea, BM Stevens, CL Jones, A Winters, S Pei, M Minhajuddin, ... Nature medicine 24 (12), 1859-1866, 2018 | 598 | 2018 |
| Inhibition of amino acid metabolism selectively targets human leukemia stem cells CL Jones, BM Stevens, A D'Alessandro, JA Reisz, R Culp-Hill, T Nemkov, ... Cancer cell 34 (5), 724-740. e4, 2018 | 465 | 2018 |
| Monocytic subclones confer resistance to venetoclax-based therapy in patients with acute myeloid leukemia S Pei, DA Pollyea, A Gustafson, BM Stevens, M Minhajuddin, R Fu, ... Cancer discovery 10 (4), 536-551, 2020 | 326 | 2020 |
| The TP53 apoptotic network is a primary mediator of resistance to BCL2 inhibition in AML cells T Nechiporuk, SE Kurtz, O Nikolova, T Liu, CL Jones, A D'Alessandro, ... Cancer discovery 9 (7), 910-925, 2019 | 267 | 2019 |
| Fatty acid metabolism underlies venetoclax resistance in acute myeloid leukemia stem cells BM Stevens, CL Jones, DA Pollyea, R Culp-Hill, A D’Alessandro, ... Nature cancer 1 (12), 1176-1187, 2020 | 188 | 2020 |
| Nicotinamide metabolism mediates resistance to venetoclax in relapsed acute myeloid leukemia stem cells CL Jones, BM Stevens, DA Pollyea, R Culp-Hill, JA Reisz, T Nemkov, ... Cell stem cell 27 (5), 748-764. e4, 2020 | 160 | 2020 |
| Cysteine depletion targets leukemia stem cells through inhibition of electron transport complex II CL Jones, BM Stevens, A D’Alessandro, R Culp-Hill, JA Reisz, S Pei, ... Blood, The Journal of the American Society of Hematology 134 (4), 389-394, 2019 | 130 | 2019 |
| MAPK signaling cascades mediate distinct glucocorticoid resistance mechanisms in pediatric leukemia CL Jones, CM Gearheart, S Fosmire, C Delgado-Martin, NA Evensen, ... Blood, The Journal of the American Society of Hematology 126 (19), 2202-2212, 2015 | 100 | 2015 |
| Targeting energy metabolism in cancer stem cells: progress and challenges in leukemia and solid tumors CL Jones, A Inguva, CT Jordan Cell stem cell 28 (3), 378-393, 2021 | 88 | 2021 |
| Characterization and targeting of malignant stem cells in patients with advanced myelodysplastic syndromes BM Stevens, N Khan, A D’Alessandro, T Nemkov, A Winters, CL Jones, ... Nature Communications 9 (1), 3694, 2018 | 79 | 2018 |
| Wnt inhibition leads to improved chemosensitivity in paediatric acute lymphoblastic leukaemia S Dandekar, E Romanos‐Sirakis, F Pais, T Bhatla, C Jones, W Bourgeois, ... British journal of haematology 167 (1), 87-99, 2014 | 79 | 2014 |
| The hematopoietic oxidase NOX2 regulates self-renewal of leukemic stem cells B Adane, H Ye, N Khan, S Pei, M Minhajuddin, BM Stevens, CL Jones, ... Cell reports 27 (1), 238-254. e6, 2019 | 74 | 2019 |
| Loss of TBL1XR1 disrupts glucocorticoid receptor recruitment to chromatin and results in glucocorticoid resistance in a B-lymphoblastic leukemia model CL Jones, T Bhatla, R Blum, J Wang, SW Paugh, X Wen, W Bourgeois, ... Journal of Biological Chemistry 289 (30), 20502-20515, 2014 | 71 | 2014 |
| The STAT3-MYC axis promotes survival of leukemia stem cells by regulating SLC1A5 and oxidative phosphorylation ML Amaya, A Inguva, S Pei, C Jones, A Krug, H Ye, M Minhajuddin, ... Blood, The Journal of the American Society of Hematology 139 (4), 584-596, 2022 | 66 | 2022 |
| The biology of relapsed acute lymphoblastic leukemia: opportunities for therapeutic interventions T Bhatla, CL Jones, JA Meyer, NA Vitanza, EA Raetz, WL Carroll Journal of pediatric hematology/oncology 36 (6), 413-418, 2014 | 52 | 2014 |
| Inhibition of amino acid metabolism selectively targets human leukemia stem cells CL Jones, BM Stevens, A D’Alessandro, JA Reisz, R Culp-Hill, T Nemkov, ... Cancer Cell 35 (2), 333-335, 2019 | 49 | 2019 |
| SIRT5 is a druggable metabolic vulnerability in acute myeloid leukemia D Yan, A Franzini, AD Pomicter, BJ Halverson, O Antelope, CC Mason, ... Blood cancer discovery 2 (3), 266-287, 2021 | 43 | 2021 |
| The metabolic enzyme hexokinase 2 localizes to the nucleus in AML and normal haematopoietic stem and progenitor cells to maintain stemness GE Thomas, G Egan, L García-Prat, A Botham, V Voisin, PS Patel, ... Nature cell biology 24 (6), 872-884, 2022 | 34 | 2022 |
| The TP53 apoptotic network is a primary mediator of resistance to BCL2 inhibition in AML cells. Cancer Discov. 2019; 9: 910–925. doi: 10.1158/2159-8290 T Nechiporuk, SE Kurtz, O Nikolova, T Liu, CL Jones, A D’alessandro, ... CD-19-0125.[Europe PMC free article][Abstract][CrossRef][Google Scholar], 0 | 30 | |
| PTPN11 mutations confer unique metabolic properties and increase resistance to venetoclax and azacitidine in acute myelogenous leukemia BM Stevens, CL Jones, A Winters, J Dugan, D Abbott, MR Savona, ... Blood 132, 909, 2018 | 23 | 2018 |
